Integrated analysis confirms decision to remove Entresto® from UM

April 1, 2020

Unique cost of care study on sacubitril-valsartan (sac-val) shows significant medical cost savings for adherent users; also, advanced analytics adds insights to impact UM for all users 

Heart failure is the leading cause of death in the U.S. Sac-val is proven to decrease hospitalization and reduce death due to heart failure with reduced ejection fraction (HFrEF), also known as systolic heart failure. 

As a knowledge management company, Prime wanted to study real world integrated benefits data on use of sac-val for adherent members, as well as all sac-val utilizing members. 

This study looked at more than 1,000 members newly initiating sac-val. For an adherent members taking sac-val, after just one year: 

  • Medical costs decreased 38%
  • Hospital costs decreased 69%
  • Emergency room costs decreased 44% 
  • Total cost of care decreased 22% 

When looking at the entire cohort (including adherent and nonadherent members), the cohort still showed a small total decrease in cost of care (2%). Prime’s recommendation to its health plan clients is to offer sac-val on an open formulary. Eliminating the prior authorization fast-tracks member access. This can save lives and health care costs.

Read more.

Sacubitril-Valsartan Real-World Assessment of Total Cost of Care and Resource Utilization Pre/Post Initiation Among Commercially Insured Members with Reduced Ejection Fraction Heart Failure (Fall 2020)

Related news


November 18, 2022

Traditional Drug Pipeline Quarterly Update: November 2022

This quarterly pipeline wrap-up provides a review of newly approved traditional drugs, recent…


November 15, 2022

Three Minutes with Mitchell Scott

Mitchell Scott is Senior Director of Prime’s Special Investigations Unit (SIU) and Pharmacy…


November 11, 2022

December 2022 decisions expected from the FDA

At Prime Therapeutics (Prime), we’ve positioned ourselves to best prepare our clients to…